$HURA News
Last published 2w ago
- 2w agoHURATuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell CarcinomaPR NewswirePreliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ETTAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA
- 4w agoHURATuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025PR NewswirePatent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the
- 1mo agoHURATuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 1mo agoHURATuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related CancersPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 2mo agoHURATuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 2mo agoHURATuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdatePR NewswireTAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to
- 3mo agoHURACG 46TH ANNUAL GROWTH CONFERENCE - TUHURA BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, everybody. Thanks for joining us at the 46th Annual Canon Core Genuity Growth Conference here in Boston. I'm John Newman, one of the biotech analysts here at the firm. Very excited to have Tahura with us
- 3mo agoHURACG 46TH ANNUAL GROWTH CONFERENCE - TUHURA BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, everybody. Thanks for joining us at the 46th Annual Canon Core Genuity Growth Conference here in Boston. I'm John Newman, one of the biotech analysts here at the firm. Very excited to have Tahura with us
- 3mo agoHURATuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 4mo agoHURATuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related CancersPR NewswireTuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 6mo agoHURATuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 6mo agoHURATuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 6mo agoHURATuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028PR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 7mo agoHURATuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 7mo agoHURATuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 7mo agoHURACraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 8mo agoHURATuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 8mo agoHURATuHURA Biosciences Announces Participation in Upcoming Investor ConferencesPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 8mo agoHURATuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related CancersPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 9mo agoHURATuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 9mo agoHURATuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous MelanomaPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 11mo agoHURATuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual MilestonePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 11mo agoHURATuHURA Biosciences Provides Corporate Update Following Recent FinancingPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 11mo agoHURATuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct OfferingPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...
- 11mo agoHURATuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and ExpositionPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 12mo agoHURATuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and ExpositionPR NewswireTuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® IndexesPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences Completes Acquisition of KinetaPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell CarcinomaPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related ProposalsPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURAFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell CarcinomaPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer ImmunotherapyPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual MeetingPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect ConferencePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)PR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual MeetingPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual MeetingPR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...
- 1y agoHURATuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program ManagementPR NewswireTuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome...
- 1y agoHURATuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdatePR NewswireTuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel...
- 1y agoHURATuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of DirectorsACCESS NewswireDr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancersDr. Tendler also oversaw 13 FDA
- 1y agoHURATuHURA Biosciences, Inc. to Present at the 37th Annual ROTH ConferenceACCESS NewswireLive webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. , a Phase 3 registration-stage immuno-oncology
- 1y agoHURATuHURA Biosciences, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceACCESS NewswireOn-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. , a Phase 3 registration-stage immune-oncology company developing
- 1y agoAKTXAMIXARECCNSP+5Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-DemandACCESS Newswire- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor
- 1y agoCARAHURAVOXXVTSKuehn Law Encourages VOXX, CARA, VTS, and HURA Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoHURATuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCACCESS NewswireTAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. , a Phase 3 registration-stage immune-oncology company developing novel technologies to
- 2y agoHURATuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" EventACCESS NewswireLive moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc.